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ABSTRACT 
 
Mucopolysaccharidosis Type I (MPS I, Hurlers Syndrome) is a lysosomal storage disease 
caused by a deficiency of alpha-L-iduronidase (IDUA). IDUA catalyzes the degradation of 
the two glycosaminoglycans (GAGs); heparin sulfate (HS) and demantan sulfate (DS). The 
accumulation of HS and DS makes MPS I progressive with inevitable degeneration of 
multiple organ systems. Accumulated excess of GAGs on the skeletal system causes 
dysostosis multiplex, atlantoaxial instability, thoracolumbar kyphosis, genu valgum, 
acetabular dysplasia, and short stature. Skeletal biomarkers of bone formation and bone 
resorption were compared in wild-type, heterozygous, and IDUAW392X mice. To 
investigate osteoblast activity, levels of the bone formation marker Procollagen type I N-
terminal propeptide (PINP) were evaluated. To investigate osteoclast activity, levels of the 
bone resorption biomarker Tartrate-resistant acid phosphatase (TRAP5b) were evaluated. 
Potential differences in serum PINP or serum TRAP5b concentrations could contribute to 
the increased cortical thickness and increased bone marrow width seen in the skeletal 
phenotype previously identified in mice with IDUA deficiency. Lastly to further 
investigate bone metabolism, transcription of six biomarkers were quantified: collagen (I), 
RANKL, OPG, TNFα, and CSF-1 isolated from tibiae of wild type, heterozygous, 
and DUAW392X mice. No significant differences were found between the genotypes for 
PINP, TRAP5b, and transcription levels of type I collagen. Lower transcriptional levels 
were found for RANKL, OPG, TNFα and CSF-1 for IDUA deficient mice compared to 
wild-type mice.  
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INTRODUCTION 
 
Mucopolysaccharidosis Type I 
 Mucopolysaccharidosis Type I (MPS I, Hurlers Syndrome) is a lysosomal storage 
disorder caused by a deficiency of α-L-iduronidase (IDUA). IDUA catalyzes the 
degradation of the glycosaminoglycans (GAGs), heparin sulfate (HS) and dermatan 
sulfate (DS). The continual accumulation of HS and DS makes MPS I a progressive 
disease with inevitable degeneration of multiple organ systems (Bach et al, 1972), 
affecting respiratory, cardiac, skeletal, ophthalmologic, and in some cases central nervous 
system function. The effect of accumulated GAGs on the skeletal system includes 
dysostosis multiplex, atlantoaxial instability, thoracolumbar kyphosis, genu valgum, 
acetabular dysplasia, and short statute. Historically, MPS I has been categorized into 
three phenotypic subtypes: Hurlers syndrome designates the severe form, Hurler-Scheie 
the intermediate form, and Scheie the attenuated form (Table 1). 
Glycosaminoglycans (GAGs) have two structural parts: a proteoglycan core and 
chains of repeating disaccharide units. The proteoglycan core consists of a serine residue 
attached to a glycine residue. The glycine acts as a linker protein between the serine 
residue and the repeating disaccharide units (Prydz K. 2015). The basic structure of  
glycosaminoglycans chains are alternating repeats of an iduronic acid (IdoA) residues 
and an amino sugar residue. The specific roles of a GAG is dependent on the complexity 
of the modifications of the chains. The specific patterns of epimerization and sulfation 
along GAG chains promote specific interactions with growth factors helping regulate 
growth, development, differentiation and immunological mechanisms (Prydz K. 2015).   
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Table One: Disease Heterogenerity 
  
 
 
 
 
 
 
 
 
 
 
 
 
Form Severity Description 
Hurler’s Syndrome High 
Early on-set rapidly progressive, 
neurodegenerative 
Hurler-Scheie’s 
Syndrome 
Intermediate 
Onset and progression between Hurler 
and Scheie extremes, with mild or absent 
central nervous system involvement 
Scheie’s Syndrome Mild 
later onset, less rapid progression, no 
neurodegeneration 
 3 
A more detailed structure of HS chains consists of repeating disaccharides of N-acetyl-d-
glucosamine (GlcNAc) and d-gucuronic acid (GlcUA) or L-iduronic acid (IdoUA) 
(Mizumoto S. et al 2015). Higher sulfated regions of HS are known to interact with 
growth factors and extracellular matrix molecules (Yoneda, A. 2012). Also, hydrated 
GAG gels have been known to play an important role for the absorption of pressure 
changes in joints and tissues (Prydz K. 2015). DS is composed of the same core protein 
but attached to N-acetyl-d-galactosamine (GalNAc) and L-iduronic acid (IdoUA) 
(Mizumoto S. et al 2015). DS is known to be an anticoagulant and antithrombotic 
glycosaminoglycan. 
In Hurler Syndrome, disease heterogeneity is a result of specific mutations 
leading to varying levels of residual activity of IDUA and accumulation level of HS and 
DS. The lower the residual activity of IDUA results in a higher severity. Without 
treatment a patient with Hurlers Syndrome will not have a life span extending past 
childhood; however the available treatment options have increased life span to early 
adulthood. Currently, MPS I treatments include: enzyme replacement therapy (ERT), 
bone marrow or umbilical cord stem cell transplantation, and corrective surgery.  
 
Treatment Options for Mucopolysaccharidosis Type I 
ERT is the use of recombinant human alpha-L-iduronidase, Laronidase, to 
simulate IDUA activity to degrade HS and DS. Laronidase was approved for treatment of 
the attenuated form of MPS I in the UK and Europe in 2004 after successful Phase III 
clinical trials. It significantly improves respiratory function and physical capacity, as well 
as reduces glycosaminoglycan storage (Wraith J.E. et al, 2005). The recombinant enzyme 
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is unable to cross the blood-brain barrier making it incapable of reducing the 
neuropathology of MPS1-H. This is not an area of concern for treatment of attenuated 
forms, since central nervous system manifestations are not observed. An inhibitory 
antibody (IgG) response to Laronidase has been observed, raising the concern as to if 
serial, life-long infusions of the recombinant protein will remain efficacious (Tolar J and 
Orchard P. 2008). In double-blind, placebo-controlled trials of laronidase, 53% of the 46 
patients had infusion-associated reactions, however they were considered to be mild, 
easily managed and decreased markedly after 6 months (Wraith J.E. et al 2004). 
Immunosuppressants, cyclosporine and azathioprine, have been seen to be successful to 
reduce the immune response (Kakkis et al 2004). Despite the available studies 
demonstrating ERT to be safe and efficacious, the long-term impact of ERT remains 
unknown (Coman D.J. et al 2008). Additionally, laronidase is not successful in treating 
the bone abnormalities in MPS I due to unknown barriers (Wraith J.E.2006).  
Benefits of ERT. In a 26-week, double-blind, placebo-controlled trial of 
laronidase were enrolled in a 3.5-year open-label extension study, patients with the 
attenuate form showed improvement in sleep apnea and increase shoulder fexion after 
infusions with Laronidase (Wraith J.E. et al 2004). Improvement was noted in the 
mobility of MPS I demonstrated in the of the 6min-walk test (6MWT), alongside 
decrease GAG content found in the urinary system and liver. 
Hematopoietic Stem Cell Transplantation (HSCT). HSCT is currently the most 
effective treatment for the more serve forms of MPS I. Bone Marrow Transplantation 
(BMT) has been used to treat MPS1-H since the first treatment in 1981 (Hobbs J.R. et al 
1981). The donor cells, taken from bone marrow or umbilical cord blood of unrelated 
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donors, secrete a functional α-L-iduronidase, capable of crossing the blood brain barrier 
to treat the neuropathology found in MPS1-H. The IDUA secreted from donor cells are 
able to cross the cellular membranes in recipient cells by the addition of a mannose-6-
phosphate residue (Hasilik A and Neufeld E 1980). After internalization, donor IDUA is 
directed to lysosomes in order to take part in degradation of heparin sulfate and demantan 
sulfate. Unfortunately, graft failure is common in MPS1 patients undergoing HSCT. One 
study concludes the cause of high graft failure is due to high concentration of heparan 
sulfate restricting stem cell migration by altering the cytokine-gradient formation 
(Watson H.A. et al 2014). Variable musculoskeletal disease progression was reported in a 
standardized follow-up study of eight children after successful stem cell transplant, 
including progression of scoliosis and acetabular dysplasia (Grigull L. et al, 2011). HSCT 
may help to slow the progression of the bone phenotype, preliminary research suggest 
improved prognosis for patients undergoing HSCT before musculoskeletal pathology 
develops. 
Unfortunately, ERT and HSCT have low efficacy in treating the skeletal 
manifestations requiring MPS1 patients to undergo surgical intervention to combat 
painful bone abnormalities. A clinical study on 72 patients with MPS1 with severe 
thoracolumbar kyphosis argues surgery is required to combat the multifactorial trunk 
imbalance despite patients receiving Laronidase with orthopedic management (Genevois 
K.A. et al, 2013). Progression of scoliosis, gibbus formation, acetabular dysplasia, coxa 
valga and compression of N. medianus (Carpal tunnel syndrome) became more 
pronounced in children after receiving stem cell transplant (Grigull L. et al 2011). 
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Replacing surgical intervention with a new therapeutic will only be plausible if the 
molecular interactions leading to the bone phenotype in MPS1 are characterized.  
Emerging Treatment Options.  In an effort to improve growth deficiencies 
found in Hunters Syndrome and Hurlers Syndrome despite treatment with HSCT and 
ERT a recombinant form of human growth hormone was developed and clinically tested. 
In the clinical study evaluating the outcome of treatment with recombinant human growth 
hormone (rGH) revealed no significant difference in growth velocity compared to 
children not treated with rGH however individual response was highly variable (Polgreen 
L.E. et al 2009). Treatment of Hurlers Syndrome with rGH is under debate due to a 
concern of increased musculoskeletal pathology (Polgreen L.E et al 2009 & Hertel N.T. 
2005). To enhance the current treatment options the limited knowledge of how 
accumulation of GAG’s alters the skeletal structure must be expanded.  
 
Skeletal Structure 
 Organization of the osteons are divided into two types of structural patterns, 
cortical bone and trabecular bone. Overall the skeletal system is comprised of 
approximately 80% cortical bone and 20% trabecular bone, although exact ratios are 
varying depending on the geometry of the specific type of bone (long, short, flat or 
irregular). Trabecular bone is found at the diaphysis of long bones, as well as in the 
pelvic bones, ribs, calvarial bone and inside vertebrae (Figure 1). Typically, vertebrae are 
approximately 25% cortical and 75% trabeculae and radial diaphysis of long bones are 
approximately 95% cortical bone and 5% trabeculae. Cortical bone is composed of 
cylindrical osteons collectively referred to as the Harversian system with 5% porosity  
 7 
  
 
Figure 1. Skeletal Structure. Cortical bone is located around the circumference of the 
bone lined by the periosteum and trabeculae (spongy bone) is located inside the 
circumference lined by the endosteum (not labeled).  
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(Figure 1). Trabeculae is composed semilunar osteons, giving the appearance of plates 
and rods. Organic material composes approximately 25% of bone tissue with type I 
collagen as the major component. The 75% of inorganic material is primarily composed 
of a network of hydroxyapatite [Ca5(PO4)OH]2. The collagen network is formed from 
collagen fibrils laid down in a lamellar pattern, this overlapping design is stronger than 
the disorganized pattern of woven bone. 
 
Bone Homeostasis 
The major function of the skeletal system is to provide structural support, 
protection of vital organs, hematopoiesis, and mineral balance. Many molecular 
interactions and pathways are involved in the process of regulating bone turnover to 
maintain the complex balance between bone formation and bone resorption. Bone tissue 
is a major storage for calcium supply, strongly linking bone homeostasis to calcium 
concentrations. Calcium is a major signaling molecule, and blood levels are tightly 
regulated. There are systematic and local factors used to regulate bone homeostasis. 
Systematic factors include parathyroid hormone, calcitonin, calcitriol, glucocorticoids, 
thyroid hormone and estrogen. When calcium concentration is high in the circulatory 
system, chief cells located on the parathyroid gland stimulate and increase intracellular 
calcium levels. The increase of calcium decreases the secretion of parathyroid hormone 
(PTH). This atypical response to hypercalcemia means PTH levels will increase when 
there are low levels of calcium. PTH directly targets bone to increase bone resorption, 
supplying the body with a source of calcium. PTH also directly affects kidney and 
indirectly affects the gastrointestinal tract to also restore circulatory calcium to basal 
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levels. PTH induces bone stromal cells to secrete cytokines, like interleukin-6 to 
stimulate bone resorption and induces osteoblasts to increase RANKL secretions and 
decreases OPG secretions to stimulate bone resorption. Both of these effects increases 
bone resorption by stimulating osteoclastogenesis. Continual elevations of PTH shifts 
bone homeostasis to have a net increase in bone resorption. However, when the elevation 
of PTH, is brief the shift will be to a net increase in bone formation because PTH also 
stimulates osteoblastogenesis and increases osteoblast survival. PTH increases 
intracellular cAMP causing a release in Insulin Growth Factor-1 (IGF-1).  
With hypercalcemia conditions, calcitonin, a 32 amino acid peptide, is released 
from perifollicular cells on the thyroid gland. Calcitonin acts directly on osteoclasts 
inhibiting bone resorption activity. Glucocorticoids decrease bone formation by 
promoting apoptosis of osteoblasts and osteocytes. Thyroid hormone provides and overall 
net increase in bone turnover, which increase bone resorption more than bone formation. 
Estrogen also inhibits osteoclasts and has antiapoptotic effects on osteoblasts thus 
resulting in an overall net increase in bone formation. Calcitriol is the active form of 
vitamin D, [1α, 25 dihyroxy-Vitamin D]. It increases the absorption of calcium by 
increase the transcellular transport of calcium in the duodenum and increases the 
resorption go calcium in the distal tubule of the kidney. Calcitriol also increases 
osteoclast number and activity.  
Osteocalcin, a biomarker for bone formation was found to be significantly higher 
in children with MPS compared to healthy children.  Bone-specific alkaline phosphatase 
(BSAP) and urinary pyridinoline also tended to be higher in MPS children. There were 
several limitations to this study including limited power to find associations due to small 
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cohort sizes. Additionally, the different forms of MPS and specific treatment plans were 
not taken into consideration, which could have influenced the levels of biomarkers. 
Lastly, reduced physical activity seen in patients with MPS1 could be primary to 
influencing bone biomarkers than accumulation of GAG influence on bone biomarkers. 
The biomarkers were not found to have an influence on bodily pain or physical-function 
scores (Stevenson D.A, et al, 2014). 
 
Basic Remodeling Unit 
 To maintain the integrity of bone the temporary anatomical structure called the 
basic remolding unit (BMU) repairs areas of bone that have sustained damage due to 
mechanical stress or cell aging (Figure 2). The BMU is composed of four cell types: 
osteoclasts, bone lining cells, osteoblasts and osteocytes. Together these four cell types 
preform the stages of bone remodeling: activation, resorption, reversal and formation. 
Osteoblasts are cuboid polarized cells responsible for laying down the collagen fibrils 
(Figure 2). They are derived from mesenchymal stem cells and eventually will give rise 
to osteocytes, bone lining cells or undergo apoptosis. Osteocytes are the main bone cell 
type, composing 90-95% of all bone cells. They develop from osteoblasts that became 
embedded in the newly formed bone matrix. Osteocytes act as mechanosensors, signaling 
for activation of bone remodeling. Bone lining cells (BLCs) are quiescent flat-shaped 
osteoblasts (Figure 2), with the ability to convert back to osteoblasts given the correct 
stimulus. The role of BLCs are still under investigation, but assumed roles include 
protecting bone from unwarranted resorption and cleaning the resorption pit to facilitate 
reversal (Everts V. et al, 2002). Lastly, osteoclasts are terminally differentiated  
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Figure 2 Bone remodeling Unit Osteoclasts are polarized bone resorbing cells derived 
from hematopoietic stem cells (on right). After bone resorption coupling signal pathway 
stimulate osteoblasts to replace the mineralized bone (on left). Osteoblast are derived 
from mesenchymal stem cells, osteoblasts and fibroblasts (not depicted here) secrete 
RANKL a ligand used to stimulate osteoclastogenesis and they secrete osteoprotegerin 
(OPG) a decoy receptor blocking RANKL from binding to its receptor RANK on pre-
Osteoclasts. Bone lining cells cover the surface of bone and do not have a clearly defined 
role. Osteocytes act as mechanosensors develop from osteoblasts that become surrounded 
by mineralized bone (Copied from Yorgan T.A. et al 2014 with permission) 
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multinucleated cells derived from hematopoietic stem cells (Figure 2). They have the role 
of resorbing bone by secreting hydrogen protons and various proteinases. Osteoclasts also 
regulate the role of osteoblasts by the secretion of cytokines and help to maintain the 
hematopoietic stem cell niche. In mice deficient in β-glucuronidase representing MPSVII,  
osteoclast morphology was seen to lack the ruffled membrane and have abnormal large 
vacuoles (Monroy M.A. et al, 2002).  
 
Osteoclastogenesis 
 Part of bone remodeling is the differentiation of hematopoietic stem cells into 
mature osteoclasts. Marrow stromal cells and osteoblasts secrete monoclonal stimulating 
factor-1 (CSF-1), Receptor Activator of Nuclear Factor κ B Ligand (RANKL) and 
osteoprotegerin (OPG) (Figure 2). CSF-1 is required for the survival and proliferation of 
osteoclast-precursors. It is also required for the survival of osteoclasts and the 
cytoskeletalon rearrangement needed for bone resorption. RANKL belongs to the TNF 
superfamily required for osteoclast maturation. RANKL binds to Receptor Activator of 
Nuclear Factor κ B (RANK) located on the membrane of the osteoclast by a signaling 
cascade not fully described, but there is an upregulation of the several transcription 
factors including NFAT2 and Fos. Osteoprotegerin (OPG), also known as 
osteoclastogenesis inhibitory factor (OCIF), is a decoy receptor for RANKL, and 
significant levels of OPG block RANKL from activating RANK (Figure 2).  
 
 
 
 13 
Bone Remodeling: Activation, Resorption, Reversal and Formation  
Activation. Each osteocyte has approximately 50 cytosolic processes that extend 
out of the lacunae and into the canaliculi connecting to neighboring osteocytes via gap 
junctions. The gap junctions formed by connexin keep osteocytes linked metabiocally 
and electrically (Clarke B., 2008). Signaling molecules, such as prostaglandins and nitric 
oxide can move rapidly through the lacunocanalicular system. Mechanical stress in weak 
bone tissue, due to age or damage, will be detected within the syncytium of osteocytes. 
The piezoelectric effect occurs in osteocytes and is the conversion of mechanical stimuli 
to biochemical stimuli. Mechanical stress has been seen to regulate Interlukin-6, 
Interlukin-7, and TNFα (García-López et al 2013). The biochemical stimuli signals for 
the activation of bone remodeling. M-CSF1 and TNFα, secreted by osteoblasts will 
stimulate osteoclastogenesis. TNFα reduces bone formation by mature osteoblasts and 
increases bone resorption by osteoclasts. Treatment on fetal calvaria precursor cells with 
TNFα reduced the cells ability to form mineralizing nodules and decreased the skeletal 
specific matric proteins osteocalcin (Gilbert L. et al 2000). It was determined by northern 
analysis that TNFα inhibited the expression of insulin-like growth factor (IGF-I) but not 
bone morphogenic factors 2, 4, or 6 or skeletal LIM protein (Gilberet L et al, 2000).   
Bone remodeling begins with the recruitment and activation of mononuclear 
monocyte-macrophage osteoclast precursors to sites of damage or weaken bone. 
Osteocytic apoptosis acts as a chemotactic signal for bone resorption, osteocytes have 
been seen to be engulfed by osteoclasts (Boabaid F. et al 2001). Multi-mononuclear cells 
fuse to form one multinucleated preosteoclast, which then attaches to the bone matrix by 
integrins binding to RGD-peptides in the matrix.  
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This fusion is formation of podosomes, an F-actin core surrounding by integrin 
and cytoskeleton proteins rich with RGD amino acids. The main connection is via the 
αvβ3 integrin binding to osteopontin and bone sialoprotein (Clarke B. 2008). Another 
connection included the intergin β1 on the surface of an osteoclast binding to collagen, 
fibronectin or laminin in the bone matrix. (Florencio-Silva et al, 2015). Formation of the 
posodome facilitates the formation of the annular sealing zone keeping the bone 
resorption pit tightly sealed for proper acidification. The number of actin rings were seen 
to be reduced in IDUA(-/-) mice by 30% compared to wild-type mice (Wilson et al, 2009). 
In a study on MPSVIII, a related lysosomal storage disease, enzyme deficient mice were 
concluded to not properly form the ruffled border by GAGs interfering with attachment 
of osteoclasts to the bone matrix (Monroy M.N. et al, 2002).  
 Resorption. Polarization of osteoclasts occurs upon attachment to the bone 
matrix, there are four domains of an activated osteoclast: sealing zone, ruffled border, 
basolateral border, and the functional secretary domain (Florencio-Silva et al, 2015). 
Bone resorption is the dissolution of hydroxyapatite crystals and degradation of the 
organic matrix by secretion of protons and proteinases from the ruffled border into the 
bone remolding compartment (BRC). The ruffled border is a membrane domain formed 
by microvilli, isolated from the surrounding tissue by the sealing zone. Phase one of bone 
resorption is dissolution of the hydroxyapatite by acidification of the BRC. Vaculolar 
proton ATPase pumps located on the ruffled border transports protons into the BRC. The 
intense concentration of protons help to dissolve the hydroxyapatite crystals by lowering 
the pH to 4.5. To sustain the electrical optimal level chloride ions are pumped via the 
choride-ion pump CIC-7. Internal pH of the resorbing osteoclast is maintained by a 
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HCO3/Cl
- exchanger located of the basolateral border. Alklation of the cells is prevented 
by HCO3
- ions also being transported into the extracellular space. Chloride ions are 
transported into the osteoclast to sustain intracellular concentration (Mulari M. et al 
2003).  
Phase two of bone remodeling is the degradation of the organic matrix by 
exposure to proteolytic enzymes. Tartrate-resistant acid phosphatase (TRAP5b), matrix 
metalloproteinase-9 (MMP-9) and cathepsin K are released into the BRC. Cathepsin K is 
a cysteine protease that degrades collagen during acidic conditions. Levels of cathepsin 
K-specific cleavage sites on type II collagen was detected by an antibody and a 
significantly lower level of cathepsin mediated neoepitope exposure on type II collagen 
was found for IDUA(-/-) mice (Model: 129:C57BL/6) compared to wild-type mice 
(Wilson et al, 2009). Also heparin sulfate and demantan sulfate have been reported to 
inhibit the activity of Cathelpsin K (Wilson, et al 2009). Degraded material and bone 
resorption proteins are endocytosed by the osteoclast and transported to the secretory 
domain (Florencio-Silva et al, 2015). Resorption results in the formation of saucer-
shaped dips called Howship’s lacunae in trabecular bone and Haversian cancels in 
cortical bone. IDUA(-/-) mice (Model:129:C57BL/6) were seen to have shallower 
resorption pits along with a lower number of pits compared to wild-type mice (Wilson et 
al, 2009). Resorption is a 2-4 week process and is regulated by RANK, OPG, IL-6, IL-7, 
CSF-1, parathyroid hormone, 1,25 D2 and calcitonin.  
 Reversal. When bone is undergoing bone remolding, there is a tight connection 
between bone resorption and bone formation. They are strongly coupled together. The 
mechanism in which resorption and formation stay tightly coupled is still under 
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investigation. One study suggests BLC have a role in coupling resorption to formation. 
After an osteoclasts leaves the how ship’s canal, a bone lining cell comes and removed 
the remaining collagen fribils that need degrading. They release a signal for osteoblasts to 
come to the canal to refill it with new bone. Proposed signaling molecules facilitating the 
transition are TGF-β, IGF-1, IGF-2, BMP, PGDF and FGF (Clarke B, 2008). TGF-β has 
been seen to correlate with bone turnover and correlate with osteocalcin and BSAP 
levels. Another proposed mechanism of reversal includes semaphorins, cysteine-rich 
signaling proteins, facilitating osteoclast-osteoblast formation. Sema4D prevents bone 
formation during bone resorption, and Sema34 on osteoblast prevent osteoclastogenesis 
(Floriencio-Silva et al 2015).  
 Formation. Finally, the last phase of bone remolding is bone formation, which 
takes between 4-6 months to complete. Osteoblasts synthesize new collagenous organic 
matrix and regulate the mineralization of the matrix. Osteoblasts regulate the 
mineralization by releasing small membrane bound vesicles with a high concentration of 
phosphate, calcium and enzymes that destroy mineralization inhibitors. The mineral 
composition of bone tissue is mostly comprised of hydroxyapatite along with carbonate, 
magnesium, and acid phosphate. Proteins that contribute to facilitating mineral 
maturation are alkaline phosphate, osteocalcin, osteopontin and bone sialoprotein. There 
are two phases to bone matrix synthesis: vesicular phase and the fibrillar phase 
(Anderson H. C. 2003) Chondrocytes and osteoblasts synthesize extracellular matrix 
vesicles designed to allow the intravesicular concentrations of calcium and phosphate to 
increase. Vesicles contain sulphanated proteoglycans that immobilize calcium ions due to 
their negative charge and they contain that immobilize phosphates. Osteoblasts release a 
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protein that will degrade sulphanated proteoglycans, thus releasing the calcium ions 
inside the vesicles. Alkaline phosphatases will degrade phosphate containing compounds 
releasing the phosphate ions inside the vesicles (Yoshiko Y. et al 2007). Phosphates and 
calcium concentrations continue to climb forming hydroxyapatite crystals. These vesicles 
also have a nucleational core composed of complex proteins in order help precipitate the 
hydroxyapatite crystals, impurities are removed as the phosphate-calcium crystals grow.  
Eventually, the vesicles will releasing the hydroxyapatite crystals into the extracellular 
matrix. The rupture of the vesicles is followed by the collagen fribrils depositing on the 
hydroxypatitie crystals.  
 
Tartrate resistant Acid Phosphatase form 5b TRAP5b  
 
The discovery of Tartrate resistant Acid Phosphatase, also referred to as Purple 
acid Phosphatase, was in the 1970’s, when it appeared as the most cathodic of five 
separate acid phosphatase bands on an acidic disc gel electrophoresis (nondenaturing 
polyacrylamide gel electrophoresis) (Li CT et al, 1970). Two bands appeared on the 
PAGE, the difference between the two bands were sialic acid residues present on the 
hand denoted as form ‘A’ of TRAP5. TRAP5a is secreted from macrophages and 
dendritic cells and is observed during inflammatory conditions. The second band on the 
gel was denoted as form ‘B’ of TRAP and is secreted from osteoclasts during bone 
remodeling. TRAP5a also has a proteasesensitivy loop-peptide not found on TRAP5b. In 
fact the proteolytic cleavage of the proteasesensitive loop-peptide by cysteine proteases is 
found to increase the activity of TRAP. In a neutral pH, TRAP acts as a generator of 
reactive oxidizing species (ROS), but in acidic conditions TRAP5b acts as a tyrosine 
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phosphatase primarily targeting the extracellular proteins attached to an aromatic ring 
such as osteopontin and bone sialoprotein (Kaija et al 2002).  
The structural design of TRAP included two sites for N-linked oligosaccharides,a 
disulfide bond, an exposed protease sensitive loop peptide and a binuclear iron center 
with 3+ ferric ions (Hallween J. 2006). Redox-state of the 2nd iron and the disulfide bond 
affects the activity of TRAP. Excision of loop and binding of mannoses may also 
increase activity.  
Vesicles containing degraded material and TRAP5b located in the resorption 
compartment are acidic allowing cathepsin K to cleave the loop-peptide, increasing the 
tyrosine phosphate activity of TRAP5b. When the vesicles move away from the 
resorption lacuna their pH is changed to neutral, providing an optimal environment for 
the ROS generating activity of TRA5b. The generation of ROS finalizes the degradation 
of the organic matrix components transcytosis to the functional secretory domain FSD. 
Degradation products and TRAP5b are released from the FSD of the osteoclast and 
released into the blood circulation. 
Recall, osteoclasts secrete protons into the bone remodeling compartment (BRC). 
Numerous clinical studies have demonstrated elevated TRAP 5b levels in bone diseases 
such as postmenopausal osteoporosis, breast and prostate cancer bone metastases, renal 
bone disease, multiple myeloma, and Paget’s disease of bone (Halleen J, 2006). 
Antiresorptive treatment efficacy studies using human in vitro osteoclast cultures have 
demonstrated that secreted TRACP 5b activity correlates significantly with both 
osteoclast number and bone resorption (Hallween J. 2006). 
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Serum TRAP5b have been seen to be a reliable indicator of bone resorption, 
correlating significantly with bone mineral density and other known markers of bone 
remodeling: bone alkaline phosphatase (BAP), osteocalcin, parathyroid hormone (PTH), 
and PINP (Shidara K et al 2008). Problems associated with using TRAP5b as a 
biomarker of bone resorption includes high diurnal variability, effects of feeding and 
renal function on the values obtained caused by the gastrointestinal hormone glucagon-
like peptide-2 (GLP-2). Also, TRAP5b is suggested to rapidly lose its activity from 
freeze-thawing cycles (Hallween J, et al 2005).  
 
Procollagen Type I N-terminal Propeptide (PINP) 
Type I Collagen is the most abundant protein found in bone composing 
approximately 90% of the extracellular matrix. It is derived from procollagen type I 
secreted by osteoblasts and fibroblasts. Biosynthesis in the fibroblasts occurs to produce 
fibroproliferative responses and in the osteoblasts for formation of the bone matrix. Type 
I collagen consists of a triple helical molecule formed from two α1 (I) chains and one 
α2(I) chain. It. In order to keep type I collagen from spontaneously aggregating into 
fibrils, it is secreted as larger precursor procollagen protein with large propeptides 
domains at the amino and carboxyl ends (Figure 3).  
Type I procollagen consists of the same structure as Type I collagen, a triple 
helical molecule formed from two pro-α1 (I) chains and one pro-α2(I) chain non-
covalently link together (L.V. Hale et al. 2006). Procollagen triple helix is flanked by 
nonhelical telopeptides and N-terminal (PINP) and C-terminal (PICP) propeptides. The 
pro-α2(I)  
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Figure 3. Bone Collagen Synthesis. New mineralized bone formation begins by 
osteoblast secreting type I procollagen. Mature type I collagen is formed after the 
cleavage of the globular propeptides, Procollagen Terminal Propeptide (PINP) and Type I 
Procollagen C-terminal Propeptide (PICP). (Figure copied from Krege J.H. et al, 2014) 
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chain lacks the N-terminal domain. The amino domain is smaller and rod-like and the 
carboxyl end is globular-like. The post-translation cleavage of the carboxyl end is 
required before the assembly of the fibrils can begin but the amino end can remain on as 
the fibril becomes thicker. Endoproteases cleaved PINP and PICP from the triple helix to 
yield Type I collagen and circulating PINP and PICP in the extracellular space. This 
newly formed Type one collagen is where hydroxypatite crystals mineralize to form new 
bone. Serum PINP concentrations are directly proportional to synthesis of type I collagen 
and bone formation.  
Serum PINP concentrations are a reliable indicator of bone formation, 
measurement of serum PINP concentration is supported by the International Osteoporosis 
Foundation, the International Federation of Clinical Chemistry and Laboratory Medicine 
and the National Bone Health Alliance as the most accurate biomarker for bone 
formation (Bauer D. et al 2012). PINP has been demonstrated as viable early serum 
biomarker in the rat for assessing bone anabolic activity. After weekly subcutaneous 
injections of PTH (1-38), a bone anabolic agent, PINP concentrations were seen to 
increase followed by an increase in bone mineral density (Hale L.V. et al 2007).After 
being released from type one procollagen, PINP is release into circulation for disposal. A 
radioactive-label pulse-chase study demonstrated the major uptake for PINP in rats was 
the liver, 78% of PINP radioactivity was recovered in isolated endothelial chief cells, 
21% in parenchymal cells and 1% in Kupffer cells. These findings indicate the clearance 
of PINP is a majority physiological function of the scavenger receptors on endothelial 
chief cells (Melkko et al. 1994). 
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When evaluating levels of bone formation, it is important to distinguish between 
the intact trimeric form of PINP and the small antigenic form of PINP. The small 
antigenic form is also referred to as the monomeric form. The trimeric form of PINP is 
the result of bone formation. The small antigenic form of PINP could originate from 
several sources including type one pN-collagens in the soft tissue and Type III pN-
collagen found in wound healing. Serum small antigen PINP could also be due to heat 
denaturation causing the dissociation with the trimeric form however this was seen to be 
unlikely. When referring to both forms (total concentration) the abbreviation is P1NP. 
Both the trimeric form and antigenic form can be found in circulation therefore 
both are located in blood serum samples used for research purposes. If an assay tests for 
total PINP the concentration of both forms will be measured. Thus intact PINP levels 
could seem to be elevated resulting in incorrectly analyzing increased bone formation. 
Assays used to analyze bone formation should only test for intact PINP. The total P1NP 
assays measures both trimeric and monomeric forms of while the intact PINP measures 
only the trimeric form (Koivula et al. 2010).  
The larger antigen is the trimeric propeptide representing the intact PINP and the 
smaller antigen contains only a single proa1-chain representing the monomeric form. The 
total molecular weight of trimeric propeptide is about 35,000kDa and its constituent 
chains 14,250KDa (proa1-chain) and 5500KDa (proa2-chain). In a study combining data 
from thermal transition, SDS-PAGE, and mass spectrometry indicate the high-molecular 
weight form of PINP represents the unstable trimeric structure. Additionally, the low-
molecular weight form represents the monomeric α1 chain released from the trimeric 
structure by heat (Brandt et al, 1999). Later, it was determine heat denaturation from 
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trimeric PINP was not a source of the small antigen form. Due to PIIINP, derive from 
collagen Type III, resulted in an increase of the small antigen form despite the fact Type 
III collagen is held together by sulfide bonds that are unbreakable by heat. From this 
study, it can be assumed the small antigen form must have another source beside heat 
denaturation of the trimeric form.  
Intact PINP is taken up rapidly by the liver. The monomeric or antigen form is 
dependent for clearance by the kidney (Koivular et al 2012). Renal insufficiency 
increases the concentration of the smaller antigen from of PINP influencing the total 
concentration of PINP seen in the assay. Other causes of increased concentration of the 
small antigen include chronic immobility, and breast cancer with metastases. . In Finnish 
blood samples patients with chronic kidney failure had a significantly higher amount of 
the monomeric form of PINP before heamdylasis. (Koivula et al 2010). PINP is liberated 
from procollagen before mineralization therefore there is no PINP in mineralized bone. It 
should be noted there is no evidence PINP would still be antigenically active when 
released from the liver after degradation. 
 
Mouse Model 
 Improvement of enzyme replacement therapy and development of novel 
treatments for MPS I was ameliorated by the generation of murine models deficient in 
IDUA. One of the first animal models, was generated by targeting disruption of the 
IDUA locus by insertion of a neomycin resistance cassette using a restriction enzyme site 
on exon VI. No detectable IDUA activity was reported for this murine model along with 
increased GAG excretion and bone abnormalities. As early as three weeks, flattened 
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facial features and thickening of digits was reported with continual progression of 
dysostosis up to 15 weeks of age. Lysosomal storage was reported to increase in several 
cell types including Kupffer cells, Glial cells, reticuloendothelial cells and splenic  
sinusoidal lining at four weeks of age; and hepatocytes, neurons, chondrocytes and renal 
tubular cells at eight weeks of age (Clarke L.A. et al, 1997).  
Further characterization of this murine model reported serve dysostosis multiplex and 
progressive neuronal degradation. Radiographic examination revealed thickening of the 
diaphysis of long bones and widening of the malar processes and zygomatic arch. In 
addition, bone histopathology revealed abnormalities in the development of the growth 
plate and –D-abnormalities on the structure of the cortical bone (L.A.Clarke et al. 1997). 
One weakness of the murine model described above is the nonspecific disruption 
the IDUA locus on exon VI, eliminating the ability to test treatment regimens on specific 
mutations. With the potential of of gene therapy for treatment, it is important to have  
small animal models with mutations analogous to human mutations in IDUA. Thus, 
another small animal model was generated using gene replacement methodology with a 
neomycin resistance cassette (Figure 4A). The replacement targeting construct contained 
the IDUAW392X nonsense mutation which is analogous to the IDUA W402X mutation 
the most common human mutation in patients with MPS I. The codon TGG was replaced 
with TAG resulting in premature termination in translation. Characterization of IDUA 
activity and GAG accumulation confirmed the mouse model exhibited similar phenotypic 
features as patients with MPS I (Wang D. et al, 2009).  
 The replacement targeting construct was composed of the IDUA exons 3-14 from 
129/SV mouse genomic DNA with the IDUA-W392X mutation (Figure 4), neomycin 
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Figure 4. Generation of the Mouse Model A) replacement targeting construct contained 
the IDUAW392X non-sense mutation and the gene for neomincin resistance B) EcoRI 
digest C) Specivty activity of IDUA in wild-type mice and two linage of IDUAW392X. 
D) Agarose Gel Electrophoresis of isolate IDUA sequence, Wild-type allele is 576bp and 
mutated allele is 610bp. (copied from Wang et al, 2009, with copyright permission) 
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resistance positive selective marker and thymidine kinase negative selective marker 
(Figure 4A). The 129/SV embryonic cells were electroporated with the targeting 
construct and successfully integrated cell clones were placed in C57BL mouse 
blastocysts. Integration was confirmed by Southern Blotting preceded by an EcoRI digest 
results in a 4.2 kb fragment for the mutated IDUA allele and a 9.9kb fragment for the 
wild-type allele (Figure 4B). The removal of the neomycin resistance cassette by 
mediated recombination left behind a 34bp fragment in an intron of the mutated IDUA 
providing a useful mechanism for genotyping (Figure 4D). The mutated IDUA allele 
results in a 610bp fragment and the wild type IDUA allele results in a 576bp fragment by 
PCR and gel electrophoresis (Wang D. et al, 2009). Biochemical characterization analysis 
of the IDUAW392X murine model reported the IDUA activity of liver and brain tissue 
samples were below the detection level in IDUA-deficient mice. Heterozygous mice were 
reported to have approximately 50% IDUA activity compared to wild-type levels. 
Analysis of GAGs reported an increased in urine excretion and tissue accumulation. Also, 
levels of IDUA mRNA transcripts were reduced in IDUAW392X mice by 30% to 50% 
compared to wild-type mice (Figure 4C). Histological analysis revealed increased 
lysosomal storage in Purkinje cells in the cerebellum and neurons in the medulla. 
Lysosomal aberrations were also confirmed by electron microscopy revealing foamy 
macrophages and increased vacuolation in IDUAW392X mice. In addition, activity of 
other lysosomal enzymes, β-D-glucuronidase and β-D-hexosaminidase, were reported to 
have increased in Idua-W392X which is thought to be compensation for the loss of 
IDUA. Finally, characterization of bone parameters were reported for the IDUAW392X 
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murine model, revealing thickening of the zygomatic arch and progressive widening of 
the femur between 15 weeks of age to 35 weeks of age (Wang D. et al, 2009).  
 
Skeletal Phenotype: Characterization of Bone Geometry and Mineral Properties  
 Currently, how accumulation of GAGs leads to the skeletal phenotype in MPS1 is 
unknown. Previous work by collaborators reported the macroarchitecture and 
microarchitecture structure are altered in IDUA (-/-) mice, along with altered 
physiochemical composition and percentage of porosity. Specifically, IDUA (-/-) mice 
were concluded to have increased femoral cortical thickness, increased bone marrow 
width and decreased femoral length. These macroarchitecture structure changes could be 
source of overall increased in bone strength. However, mineral composition findings 
suggested IDUA (-/-) mice may have weaker bones (Oestreich A.K. et al, 2015).  
Tibial microarchitecture. Tibial microarchitecture was analyzed using 
microcomputed tomography (µCT) and compared between wild-type, heterozygous, and 
IDUA (-/-) mice. Cortical thickness, trabecular number, and connectivity density  
significantly increased in female IDUA (-/-) mice and cortical thickness was significantly 
increased in male IDUA (-/-) mice compared to wild-type mice. Trabecular separation 
significantly decrease in female IDUA (-/-) mice. Despite only cortical thickness increasing 
significant in males, other male microarchitecture properties showed similar trends as the 
female IDUA (-/-) mice (Oestreich A.K. et al, 2015). 
Bone Mineral Density Distribution and Porosity. Quantitative backscattered 
electron scanning was used to analyze bone mineral density distribution (BMDD) and 
porosity using the calcium content in relation to atomic number (Figure 5). Wild-type 
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mice and IDUA(-/-) mice were determined have equivalent BMDD at the mid-diaphysis of 
the tibia. Also, IDUA(-/-) mice were seen to have a 50% increase in porosity compared to 
wild-type mice (Oestreich A.K. et al, 2015). 
Material and Physiochemical Properties. Raman Spectroscopy was utilized to examine 
tibial mineral and matrix composition by quantifying the carbonate/phosphate ratio 
(CH3
2-/PO4
3-), mineral/matrix ratio (PO4
3-/CH2) and mineral/collagen ratio (PO4
3-/amide 
I) (Figure 6). Area of hydroxyapatite is assumed to equal to PO4
3- levels. No change 
mineral compositions were reported between male wildtype mice, heterozygous and 
IDUA (-/-) mice. Differences identified for female IDUA(-/-) mice were an increase in the 
carbonate/phosphate ratio along with decreases in the mineral/bone matrix ratio and 
mineral/collagen ratio in IDUA(-/-) mice. Although the decrease in mineral/collagen ratio 
did not research significance (Oestreich A.K. et al, 2015). The increase of carbonate as a 
substitute for phosphate was suggested to be an indication of more mature bone matrix. It 
is unclear if there is a decreased in mineral or increase in collagen altering the other ratios 
measured. The altered physiochemical properties could account for the decreased 
strength suggested the biomechanical integrity properties tensile strength and shear 
modulus of elasticity. 
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Figure 5. Bone mineral density distribution (BMDD) and porosity analysis as 
determined by scanning electron microscopy. Representative segments of female A) 
Wt, B) IDUA+/− ,and C) IDUA− /− cross-sectional BMDD images of the medial section 
of the mid-diaphysis of the tibia (range of 256 graylevel numbers, with red representing 
the greatest density of calcium and blue the least).For each sample the whole cross-
sectional image was used to determine the BMDD histogram. (Copied from Oestreich 
A.K. et al, 2015 with permission) 
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Figure 6. Physiochemical composition of the tibial cortical bone was determined 
using Raman spectroscopy.A) Carbonate/phosphate ratios[(CO3
2− /PO4
3− ); indication of 
carbonate substitution of phosphate in the crystal lattice] were increased in tibiae from 
IDUA− /− females (white bar) compared to Wt (black bar). B) Phosphate to bone matrix 
ratios [(PO4
3− /CH2); indication of the relative amount of mineral phosphate to organic 
matrix] was decreased in tibiae from IDUA− /− females compared to Wt and IDUA+/− 
(graybar) littermates of the same sex. C) Phosphate to collagen ratios [(PO4
3− /amide I); 
indication of the relative amount of phosphate mineral to collagen] was decreased in 
tibiae from female IDUA− /− compared to IDUA+/− littermates and had a decreased trend 
compared to sex-matched Wt littermates (p= 0.06). Values are means ± SE. ap ≤ 0.05 
compared to sex-matched Wt,bp ≤ 0.05comparedtosex-matchedIDUA+/− ,cp ≤ 0.05 
compared to genotype-matched male. Male Wt (n = 5),IDUA+/− (n = 5),and IDUA− /− (n = 
4); Female Wt (n = 5), IDUA+/− (n = 4), and IDUA− /− (n = 5). (Copied from Oestreich 
A.K. et al, 2015 with permission) 
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Femoral Geometry and Biomechanical Strength. Femoral length was found to 
be reduced in IDUA (-/-) mice compared to wild-type and heterozygous females by µCT 
analysis. As well as, increased midshaft marrow diameter and increased cortical  
 bone width. Torsional strength is described as the maximum stress a material can 
withstand before failing under torsion while energy loading to failure is the amount of 
energy absorbed by the material before rupture. Both male and female IDUA (-/-) mice 
were reported to have increased torsional ultimate strength and increased energy loading 
to failure (Figure 7A-C). Tensile strength is defined as max stress a material can endure 
before failing while force is applied at both ends in opposite directions. Female IDUA (-/-) 
mice were observed to have significantly decreased tensile strength and male IDUA(-/-) 
mice were observed to have decrease tensile strength however it did not reach statistical 
significance (Figure 7D). Notably, torsional strength and tensile strength exhibited 
opposite affects for bone strength of IDUA (-/-) mice. Torsional stiffness is the ratio of 
applied torsion to the angle of the force, there was no difference seen between genotypes 
for torsional stiffness (Figure 7E). There was a significant different for shear module of 
elasticity (Figure 7F).  Elastic modulus is an intensive property of the material and 
stiffness is an extensive property of the structure. Overall the adverse changes in the 
material and physiochemical properties in bone strength are compensation by the changes 
to microarchitecture and geometry. 
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Figure. 7. Bone biomechanical integrity. A) Representative torsional loading to failure 
graphs from female Wt (black bar), IDUA+/− (gray bar),and IDUA− /− (white bar) 
femora.B) Energy to failure (U; the amount of energy the bone can absorb prior to 
fracture as measured by the area under the torque: angular displacement graph) of female 
IDUA− /− femora is increased compared to sex-matched Wt and IDUA+/− littermates. C) 
Torsional ultimate failure (Tmax; the force at failure as measured by the peak of the 
torque: angular displacement curve) was increase in both male and female femora from 
IDUA− /− compared to sex-matched Wt and IDUA+/− littermates. D) Tensile strength 
(Su;the strength of the bone material as measured by subtracting the estimated strength 
contribution of the geometry component from the Tmax) is decreased in femora from 
female IDUA− /− compared to sex-matched Wt littermates. E) Torsional stiffness (Ks;the 
stiffness of the bone as measured by the slope of the torque: angular displacement curve 
between 5 and 10 Nmm) is equivalent among all genotypes assessed. F) Shear modulus 
of elasticity (G; an estimate of the elasticity of the bone material as measured by the Ks—
the estimated contribution of the geometry component) is reduced in femora from female 
IDUA− /− compared to sex-matched WT and IDUA+/− littermates.ap ≤0.05 compared to 
sex-matched Wt,bp ≤0.05compared to sex-matched IDUA+/− ,cp ≤0.05 compared to 
genotype-matched male. Male Wt (n= 8), IDUA+/− (n= 6), and IDUA−/− (n= 7); Female 
Wt (n= 8), IDUA+/− (n= 8), and IDUA−/− (n= 5). (Copied from Oestreich A.K. et al, 2015) 
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Skeletal Phenotype: Characterization of Bone Remodeling Biomarkers 
It is the goal of this work to help elucidate the cause of the bone phenotype seen 
in MPS I by analyzing bone remodeling. Skeletal biomarkers of bone formation and bone 
resorption will be compared in wild-type, heterozygous, and IDUA (-/-) mice.  
To investigate osteoblast activity, levels of the bone formation marker PINP were 
evaluated in wild type, heterozygous, and IDUA(-/-) mice. Levels of osteoclast activity 
were investigated by determining levels of serum TRAP5b a marker for bone resorption. 
PINP is strongly influenced by circadian rhythm and food intake so samples should be 
collected during the morning fasting state do decrease variance TRAP5b is secreted 
exclusively from bone-resorbing osteoclasts providing a reliable tool for measuring 
osteoclast activity. Potential differences in serum PINP or serum TRAP5b concentrations 
could contribute to the increased cortical thickness and bone marrow width seen in the 
skeletal phenotype previously found in mice with an IDUA deficiency. 
Lastly to further investigate bone turnover levels, transcription of the several 
biomarkers for bone metabolism were quantitated by measuring the mRNA levels of: 
alpha chain I and alpha chain 2 of type one collagen, RANK, OPG, TNF-α, and CSF-1 in 
the tibiae of wild type, heterozygous, and IDUA(-/-) mice. Collagen is the most abundant 
protein in bone, it is important to determine if a deficiency in IDUA alters the levels of 
two types of alpha chains of type one collagen. Since type one collagen is the main 
component of the organic extracellular matrix discrepancies of type one collagen 
transcription levels can indicate if bone formation levels are altered between the 
genotypes. 
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 Decreases in RANK and CSF-1 or increases in OPG may decrease 
osteoclastogenesis causing a decrease in osteoclast activity. TNFα stimulates 
osteoclastogenesis via RANK/RANKL independent and RANK/RANKL dependent 
pathways, evaluating mRNA levels for TNFα could help determine in levels of bone 
resorption are altered in mice with IDUA deficiency compare to wild-type mice. 
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EVALUATION OF BONE RESORPTION BY COMPARING LEVELS OF 
TRAP5b 
 
Materials and Methods  
To compare osteoclast activity by genotype, the levels of Tartrate Resistant Acid 
Phosphatase form 5b (TRAP5b) were measured using Enzyme Linked Immunosorbent 
Assay (ELISA) from Immunodiagnostic Systems (IDS Code# IS-4000). In this technique 
concentraion of TRAP5b are measured by direct correlation with the absorbance of a 
substrate. Each well is coated with a primary antibody that will bind to TRAP5b which is 
present in the sample. The blood serum samples collected from the IDUAW392X linage 
are allowed sufficient time to bind to the primary antibody. A secondary antibody is 
washed over the plate and binds to TRAP5b. The technique is referred to as a sandwich 
ELISA due to the target being bound to an antibody on either side. A third antibody is 
then washed over the plate, this antibody is attached to a substrate. When a stop solution 
is washed over the plate, the substrate becomes fluorescent. The absorbance (405nm) is 
measured for each well and the level of TRAP5b can be calculated using the standard 
curve generated from the calibrators (provided in the IDS kit).  
Blood serum samples were received from collaborators, Dr. Charlotte Phillp’s lab 
at the University of Missouri. All samples were stored at -80°C until TRAP5b 
measurement and thawed on ice before transferred in 96 well plate. Anti-mouse antibody 
was reconstituted by adding 10.5 ml of Millipore water, inverted and let to incubate at 
room temperature for 15 minutes. The reconstituted anti-mouse antibody (100 µl) was 
added into all wells and incubated on a shaker for an hour at room temperature. 
Calibrators 0-4 and the control were reconstituted with 0.5 ml of Millipore water, mixed 
by inversion and incubated at room temperature for 15 minutes. The antibody coated 
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plate was manually washed four time by adding 250 µl of Wash Buffer to remove excess 
anti-mouse antibody. Calibrators and the control (100µl of each) were loaded into wells, 
wash buffer was not added to calibrator or control wells. Serum samples (25 µl) were 
added to wells containing 75 µl of the 0.9% Sodium Chloride Dilution Solution. 
Releasing Reagent (25 µl) was added to all wells.  
The plate was incubated at room temperature for one hour while slowly shaking. 
The substrate solution was prepared by dissolving the substrate tablet into 5 ml of 
substrate buffer as directed by the kit. The wash step was repeated as done previously. 
Fresh substrate solution (100µl) was added into all wells. The plate was sealed and 
incubated at 37˚C for 2 hours. Stop solution (25µl of 0.32M Sodium hydroxide solution) 
was added to all wells. The absorbance of all wells was read at 405nm using a 
SpectraMax Paradigm Multi-Mode Detection Platform platereader.  
Calibrators were run in duplicate on every plate, absorbance was averaged and 
used to generate the calibration curve. The calibration curve was created by plotting the 
Log of the average absorbance versus the Log of the calibrator’s concentration. The 
concentrations of the calibrators and the control range were provided by the IDS kit. The 
calibration curve was verified by ensuring that the absorbance of the control generate a 
concentration within the provided range. One-way ANOVA statistical tests were used to 
evaluate the effect genotype had on TRAP5b concentrations (SAS Program GLM for 
Unbalanced ANOVA).  
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Results 
One-Way ANOVA (GLM procedure) reported no statistical difference in 
TRAP5b concentrations between the genotypes (F= 1.33, PR 0.2736) The mean 
concentration for TRAP5b for male wildtype animals was 5.00 U/L (SD=2.53, n=7) 
(Table 2). The mean TRAP5b concentration for male heterozygous animals was 3.62 U/L 
(SD=0.868, n=12) and the mean TRAP5b concentration for male IDUA(-/-)  mice was 
4.581 U/L (SD= 2.031, n=7 ). (Table 2). The mean concentrations for female wildtype 
mice was 5.676 U/L (SD= 2.571, n=7). (Table 2). The mean concentration for female 
heterozygous mice was 4.583 U/L (SD= 1.464, n=6) (Table 2) and for female IDUA(-/-) 
mice was 4.029µg/L (SD=0.1.311, n=5) (Table 2). One-way ANOVA (GLM procedure) 
found no significant difference for the mean concentrations of TRAP5b between the 
genotypes for males and females, (males; F= 2.28, p= 0.1162) and (Females; F= 1.77, 
p=0.1833).  
Bartlett’s test of homogeneity for Variance reported the statistical difference 
should be evaluated using Log of TRAP5b; (TRAP5b; PR= 0.0391), (LogTRAP5b; PR= 
0.2889) (Table 2). One-way ANOVA showed no statistical difference for the Log 
concentration of TRAP5b between genotypes (F=0.12, PR= 0.4212) (Figure 8). 
Discussion and Conclusion 
During bone resorption, vesicles containing TRAP5b are released from the ruffled 
border domain of a polarized osteoclast into the acidic bone remodeling compartment 
(BRC). TRAP5b helps to degrade the organic matrix thru tyrosine phosphatase activity. 
Degraded material leaves the BRC and is directly absorbed by the extracellular matrix 
underneath the sealing zone or the degraded material is transported to the functional  
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Table 2. Means and standard deviations for TRAP5b concentration (U/L) and Log 
TRAP5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  TRAP5b Log TRAP5b  
Sex Genotype 
MEAN 
(U/L) 
Std Dev 
MEAN 
Log 
(U/L) 
Std Dev n 
Male 
WT 5.007 2.528 0.648 0.234 7 
HET 3.623 0.868 0.547 0.105 12 
IDUA(-/-) 4.811 2.031 0.653 0.164 7 
Female 
WT 5.676 2.571 0.712 0.211 7 
HET 4.583 1.464 0.640 0.15328 6 
 IDUA(-/-) 4.029 1.311 0.589 0.126 5 
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Figure. 8. Levels of Tartrate Resistant Phosphatase Form 5B (TRAP5b). Levels 
determined by Enzyme Link Immunosorbent Assay (ELISA) to evaluate bone resorption 
in Wild-type (Wt), Heterozygous HET) and IDUA(-/-) mice. Male Wt (n= 7), HET (n= 
12), IDUA(-/-) (n= 7); Female Wt (n= 7), HET (n= 6), and IDUA(-/-) (n= 7). One-way 
ANOVA (GLM procedure) reported no significant difference for the mean concentrations 
of TRAP5b between the genotypes (F= 1.33, p= 0.2736). Bartlett’s test of homogeneity 
for Variance (Pr > F 0.0391) reported the statistical difference should be evaluated using 
Log phase of TRAP5b. One-way ANOVA showed no statistical difference for the Log 
concentration of TRAP5b (F=0.12, p= 0.4212). 
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secretory domain (FSD) of the osteoclast by intracellular vesicular trafficking. As the 
vesicles move away from the resorption lacuna to the FSD their pH increases to a neutral 
level, providing the optimal environment for the reactive oxidizing species (ROS) 
generating activity of TRAP5b. This capability of ROS activity of TRAP5b has been 
proposed to indicate TRAP5b helps to further degrade the remaining collagen fragments 
inside the intercellular vesicles by producing hydroxyl radicals (Kaija H et al 2002 & 
Vääräniemi J et al 2004).  
Unexpectedly, TRAP5b concentrations were not seen to be significantly different 
between wild-type, heterozygous, and IDUA(-/-) mice even though the IDUAW392X 
mouse model was demonstrated to have increased cortical width and bone marrow 
diameter (Figure 8). It is reasonable to assume changes in the balance of bone remolding 
contribute at some level to the changes in bone phenotype seen in IDUA(-/-) mice 
compared to wildtype. TRAP5b has been observed to be a reliable marker of bone 
resorption yet no changes were seem in TRAP5b concentration to support the hypothesis 
of altered levels of bone remodeling. Either levels of bone resorption are not affected by 
accumulation of GAGs, enzymes other than TRAP5b are involved, or the effect of GAGs 
accumulation has on bone resorption is mediated by another mechanism.  
Raman spectroscopy and µCT reported equivalent cortical density in wildtype 
mice and IDUAW392X mice (Figure 6). There is a possibility that the accumulation of 
heparin sulfate (HS) and dermatan sulfate (DS) does not alter levels of osteoclast activity. 
However this seems unlikely due to the change in bone phenotype. It is also seems 
unlikely the copious amount of DS and HS would not have some effect on the dynamics 
between osteoblasts, osteocytes, bone lining cells and osteoclasts.  
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It has yet to be determined if TRAP5b is an adequate indicator of osteoclast 
activity or osteoclast number. TRAP5b activity has been proposed to remain at constant 
levels regardless of level of bone resorption as TRAP5b is cleaved and excytosed at the 
same rate in resorbing and nonresorbing osteoclasts (Hallween J. 2006). However other 
sources conclude TRAP5b is an indicator of osteoclast activity. Regardless of TRAP5 
levels indicating osteoclast number or osteoclast activity TRAP5b can provide insight on 
the levels of bone resorption.  
 Ultrastructural analysis revealed abnormal osteoclastic morphology in a 
Mucopolysaccharidosis type VII (MPS VII) mouse model. A similar inherited lysosomal 
storage disease caused by a deficiency in β-glucuronidase (Monroy M.A et al 2002). 
Osteoclasts failed to form ruffled border membranes and many appeared to be detached 
from the bone surface. Proper attachment of the osteoclast by the sealing zone domain is 
important for proper degradation of the hydroxyapatite and organic matrix. In fact 
Monroy M.A. et al observed significantly smaller and fewer resorption pits formed by 
osteoclasts derived from the β-glucuronidase deficient mice compared to osteoclasts 
derived from normal mice (2002). 
It is not unexpected for TRAP5b serum concentration to be unaltered in IDUA-
W392X mice if TRAP5b is an indicator for number of osteo85s as opposed to indicating 
osteoclast activity. Bone resorption could be lower in IDUA(-/-) mice without effecting the 
level of osteoclast number. Bone resorption could still be decreased if osteoclasts are 
unable to form tight attachment to the bone matrix due to the accumulation of heparin 
sulfate (HS) and dermatan sulfate (DS).  
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If TRAP5b is an indicator of osteoclast number, serum concentration of TRAP5b 
could be altered if there was an increased in osteoclastogenesis. To evaluate the levels of 
osteoclastogenesis the expression levels of M-CSf-1, RANK and OPG were evaluated in 
the next part of the study by comparative qPCR.  
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EVALUATION OF BONE FORMATION BY COMPARING LEVELS OF 
PROCOLLAGEN TYPE I N-TERMINAL PROPEPTIDE (PINP) 
 
 
Materials and Methods  
Enzymeimmunioassy (EIA) kits (Cat# SB-TR201A) purchased from IDS 
(Immunodiagnostics Systems) were used to measure the trimeric, intact form of PINP in 
serum from wildtype, heterozygous and IDUA(-/-) mice. The assay is specific for 
measuring bone formation as it does not measure the total concentration (P1NP) by 
including the small antigen form. EIA, a competitive assay was used in place of the 
traditional “sandwich” enzyme-linked immunosorbent assays ELISA technique due to the 
small size of PINP. Steric hindrance prevents two antibodies binding to PINP at the same 
time. The EIA kits were stored at 4°C until use. 
 Blood serum samples were received from collaborators, Dr. Charlotte Phillp’s lab 
at the University of Missouri. All samples were stored at -80°C until PINP measurement 
and thawed on ice before transferred in 96 well plate. All Calibrators (0-4) and controls 
(1-2) were reconstituted with 5ml of Millipore water, biotin was reconstituted with 8ml of 
Millipore water and all were left at room temperature for 15 minutes. Remaining 
calibrators and controls were stored 4°C between trials and remaining biotin was stored at 
4°C between trials. The concentrated wash solution was added to 950ml of Millipore 
water and stored at room temperature.  
Calibrators and controls were added (50µl) to appropriate wells on a standard 
clear 96well microtiter plate. Serum sample were added in triplicate at 5µl per well 
followed by 45 µl of sample diluent. All samples were added within 15minutes of each 
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other as directed by the kit. Sample numbers included 292, 307, 308, 311, 313, 331, 341, 
354, 355, 359, 364-369, 375, 376, 379, 380-382, 401, 402, 404, 406, 407, 409, and 410. 
Samples are allowed to bind to the primary antibody attached to the bottom of the wells. 
The PINP-biotin was added (50µl) to calibrators, controls and sample wells, and any 
primary antibody not bound to PINP will bind to the PINP-Biotin complex. The plate was 
covered with an adhesive plate sealer and incubated at room temperature for 60 minutes 
shaking at 500 to 700rpm. Each well was washed three times with 250µl of Wash 
solution.  
Enzyme conjugate (150µl) was added to all wells, this secondary antibody binds 
to the PINP-Biotin. The plate was covered and incubated at room temperature for 30 
minutes followed by a repeat of the three wash steps. The color substrate, 
Tetramethylbenzidine (TMP), was added (150µl) to all wells and will bind to the enzyme 
conjugate. TMP was added in the dark due to risk of degradation when exposed to ultra 
violet light. The plate was covered and incubated in the dark for 30 minutes at room 
temperature. Hydrochloric acid was added (50µl) was added to stop the reaction. Optical 
densities (OD) were recorded at 450nm and 652nm with SpectraMax Paradigm Multi-
Mode Detection Platform. In a pH neutral environment TMB exists as a pale blue charge-
transfer complex of the parent dimine and diimine oxidation product with max 
absorbance wavelengths at 350nm and 652nm (Josephy PD et al, 1982). In an acidic 
environment TMB is oxidized to a yellow diimine with a max absorbance wavelength at 
450nm (Josephy PD et al, 1982). The OD at 605nm represents the absorbance of residual 
color substrate (TMP) not oxidized by HCl (Figure 9). 
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Figure 9.  Colorimetric Oxidation of Tetramethylbenzidine TMP used to detect 
levels of PINP. In a pH neutral environment TMB exists as a pale blue charge-transfer 
complex of the parent dimine and diimine oxidation product with max absorbance 
wavelengths at 350nm and 672nm In an acidic environment TMB is oxidized to a yellow 
diimine with a max absorbance wavelength at 450nm. (Copied from Li B, Du Y, Li T, 
Dong S, 2009, with permission) 
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The difference of OD605nm and OD450nm for the calibrators, controls and samples 
was calculated. A standard curve was created from the OD calibrators as a 4-parameter 
logistic curve fit by the free online data analysis software: ELSIAanalysis.com. Intact 
PINP concentration for the samples were calculated based on the regression equation 
produced from the standard curve. The statistical software IBM SPSS was used to 
perform the Turkey’s Least squares significance test and Levene's Test of Equality of 
Error Variances with help of the RSTATS team at Missouri State University. The 
concentration of PINP was tested for differences among genotypes using sex as a 
covariate, differences were considered significant at p< 0.05.   
 
Results 
 The average concentration of PINP for wildtype mice was 13.9 µg/L (SD=13.4, 
n=9). For heterozygous mice, the average concentration was 25.8 µg/L (SD=30) (Table 
3). No significant difference was observed between the genotypes. Average 
concentrations were evaluated in male and females to determine if difference exists 
between the sexs. Average concentration for males were wild-type mice was 11.2 µg/L 
(SD=13.2, n=5) (Table 3). The average concentration for heterozygous mice was 17.6 
µg/L (SD=23.3, n=4). The PINP concentration for IDUA(-/-) animals was 29.6 µg/L 
(28.1, n=6) (Figure 10). For females the average concentration for wildtype animals was 
17.3 µg/L (SD=14.9, n=4) and for heterozygous animals was 30.0 µg/L (SD21.8, n=8). 
The average PINP concentration for IDUA(-/-) mice was 3.27 µg/L (SD=0.77, n=3) 
(Table 3, Figure 10). No significance was found between the genotypes using sex as a 
covariate.  
 47 
 
 Table 3.  PINP Statistical Comparison 
 
 
 
 
 
 
 
 
 
 
 
 
Sex Genotype 
Average 
Concentration 
(ng/L) 
Concentration 
Range 
Standard 
Deviation 
Standard 
Error of 
Means 
(SEM) 
 
 
n 
 
MALE 
Wt 11.23 4.01-34.90 13.26 5.93 5  
HET(+/-) 17.63 4.66-52.43 23.33 11.67 4  
IDUA(-/-) 29.67 3.29-75.85 28.11 11.47 6  
FEMALE 
WT 17.31 4.39-30.25 14.87 7.43 4  
HET(+/-) 29.95 2.87-81.67 21.80 7.71 8  
IDUA(-/-) 3.27 2.53-3.66 0.77 0.45 3  
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A high level of variability was found in all genotypes and sexs as evident by the reported 
standard deviations (Table 4). Levene's Test of Equality of Error Variances indicated 
wild-type mice had significantly higher variability than heterozygous and IDUA(-/-) 
animals.  
Discussion and Conclusions 
Procollagen Type I N-Terminal Propeptide (PINP) is cleaved from type I 
procollagen before mature type I collagen can be mineralized into bone tissue. The only 
source of intact PINP in the serum is that which is cleaved from type I procollagen; 
therefore the concentration of intact PINP is a biomarker to evaluate levels of bone 
formation. As mentioned previously, mice with MPS1 have been found to have 
alterations in the skeletal geometry, microarchitecture, biomechanical properties, and 
physiochemical properties. Geometric skeletal changes include thicker cortical bone 
width, increased marrow diameter and decreased femur length. The primary objective of 
this study was to investigate the source of the altered bone geometry and properties by 
determining if there were altered levels of bone formation or bone resorption in IDUA 
deficient mice compared to wild-type mice and heterozygous mice. 
There were no significant differences found in the level of PINP across genotypes 
as determined by the EIA (Figure 12). There was a wide range of concentrations seen in 
data points. A majority of samples fell between 3 and 10 ng/L of PINP but every other 
category besides female IDUA(-/-) mice included data points over 30 ng/L and even 80 
ng/L (Table 3). Low levels of standard deviation, error and variability reported for the 
sample population of female IDUA(-/-) mice should not be assumed to be accurate for the 
total population of female IDUA(-/-) mice due to the low sample number, n=3. If the 
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sample number increased it is assumed the variability would also increase following the 
trend observed in the wildtype mice, heterozygous mice, and male IDUA(-/-) mice. 
 The source of variability in the levels of PINP is unclear, but has been previously 
reported to include the pre-analytical variables including circadian rhythms, fasting state, 
age, recent fracture and mineral levels. If samples were collected at the same age and in 
the early morning fasting state the preanalytical variables of circadian rhythms, fasting 
state and age should have nullified (Schlemmer A., Hassager C., 1999). It is unclear 
when the sample collection time occurred for experimentation on PINP and TRAP5b.  
Also estrogen levels were controlled for since all blood serum samples were collected at 
4 months of age for mice of the same gender to have similar sexually maturity. Estrogen 
levels could be different between the sexes, which is the basis for using sex as a 
covariate. Estrogen plays a significant role in bone homeostasis by inhibiting osteoclast 
activity (Pacifici R 1996) and having antiapoptotic effects on osteoblasts and osteocytes 
(Kousteni S. et 2002, Kousteni S. et al 1997 & Emerton K. B. et al 2009). Overall 
estrogen provides an increase in bone formation and a decrease in bone resorption 
(Khosla S. et al 2012).  
Activity Level. Not all variables influencing bone turnover can be limited by 
uniform serum collection including physical activity level.  Male mice with an IDUA 
deficiency have been observed to be less active than there wild-type and heterozygous 
littermates. Bone turnover is directly affected by physical activity (load degree) and it is 
indirectly affected through the activation of several endocrine molecules such as 
Interleukin-6 and Interluckin-7 (Lombardi G. et al, 2015). Important questions are, 
whether higher activity levels may be stimulating bone remodeling or could inactivity be 
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having an effect on the dynamic relationship between osteoblast, osteoclasts and 
osteocytes. Activities levels were not quantified, in order to validate this observation 
activity levels would need to be proved to be significantly different between wild-type 
mice and IDUA(-/-) mice. The observation of male IDUA deficient mice being less active 
and less aggressive will be negated if proven false. Another weakness to this argument is 
it probably cannot be applied to female IDUA(-/-) mice as females are assumed to have 
similar active levels across genotypes.  
Recent fracture. Recent fracture has also been shown to increase bone turnover. 
One possibility is male wild-type mice higher activity levels leads them to be more 
aggressive which could result in higher fracture rates. Therefore, if IDUA deficiency 
resulted in an alteration in bone formation the potential higher activity levels seen in 
wild-type mice could be masking the difference caused by GAG accumulation. This 
effect of increased aggressiveness would only be observed in male mice, both wild-type 
and IDUA females do not typically demonstrate aggressive behavior. 
Previous Research. Children with MPS I were found to have increased serum 
osteocalcin levels with trends of increased serum bone alkaline phosphatase (BSAP) 
levels compared to age-matched unaffected children (Stevenson D.A. et al 2014), 
oseocalcin and BSAP are specific to osteoblasts and can be used to compare levels of 
osteoblast number and activity.  Oestreich (2015) suggested there was increased bone 
formation in children with MPS I, however with compromised function.  
Porosity was also observed to be 50% higher in IDUA (-/-) compared to wild-type 
males by quantitative back scattered electron microscopy (Figure 6). The increase of 
porosity is assumed to be higher levels of lacunae where osteocytes are located. 
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Osteocytes are derived from osteoblasts that enclosed itself with newly formed bone 
tissue. Collectively, previous research demonstrates an increased in osteoblast activity. 
The increase in osteoblast activity supports the question, why was there not a significant 
increase in the bone formation marker PINP in IDUA (-/-) mice compared to wild-type?  
One theory could be the accumulation of GAGs does not alter the signal preceding the 
secretion of PINP from osteoblasts. Rather the accumulation affects the downstream steps 
of type I collagen into integration into the bone matrix.  
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EVALUATION OF BONE REMODELING BY QUANTITATION OF mRNA 
TRANSCRIPTS 
 
Materials and Methods 
 RNA isolation. Previously harvested snap frozen tibiae were removed from 
storage at -80°C and placed on liquid nitrogen. The tibiae (n=36, 12 for each genotype) 
were rapidly crushed with a hammer and homogenized in 500 ml of Denaturing solution 
(4M guanidinium Thiocyante, 25mM sodiumcitrate, pH 7.0, 0.5% (w/v) Sarkosyl and  
0.1M 2-mercaptoethanol) with the MultiGen 7xL homogenizer. Phenol-chloroform 
extraction was then used to isolate the nucleic acids. Sodium Acetate (2M pH 4.0) was 
added and the solution mixed by inversion. Acid-phenol:Choloform:Isoamyl (24:24:1) 
was added, the solution was quickly mixed by vortex, allowed to cool on ice and 
centrifuged at 4°c until separation of the organic phase and aqueous phase was complete. 
RNA was precipitated with 500µl of Isopropanol and the supernatant was discarded. 
RNA was further purified using the Qiagen RNA Isolation Spin Column Kit. 
Concentration of isolated RNA was quantified by reading the 260nm and 280nm 
absorbance values using the Nanodrop. (Protocol from Chomozynski and Sacchi, 2006 
edited by Arin Kettle Oestreich) Samples (n=30) were diluted into 10 µl aliquots 
containing 2 µg of RNA. RNA was transcribed into cDNA by using Reverse-
Transcriptase PCR (Life Technology’s High Capacity RNA-to-cDNA kit 
Lot#00282389). Six of the isolated RNA samples had concentrations less than 2ng which 
is below the optimal concentration to use for RT-PCR.  
 Comparative qPCR. SYBR™ Primer/Probes sets were purchased from Applied 
Biosystems. Cycle Threshold (Ct) is the cycle in which amplification reaches above 
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background noise, with Ct being inversely related to cDNA is present in the sample. The 
Ct values for the genes of interest were normalized to the housekeeping genes GAPDH 
(Glyceraldehyde 3-phosphate dehydrogenase) and PGK1 (Phosphoglycerate Kinase 1). 
Normalizing genes were verified to have consistent expression in wild-type (n=2) and 
IDUA(-/-) mice (n=2) (Table A1). The normalized expression values for heterozygous and 
IDUA(-/-)  are relative to the normalized expression value of wild-type. Expression values 
were found to be significant if p>0.05 uses a two-sided student t-test. (CFX Manager 
Software Version 3.0) Regulation is the measurement of the change of the relative 
normalized expression compared to the control (Bio-rad CFX Manager Software guide 
#10021337).  
 Agarose Gel Electrophoresis. In order to verify amplification of the correct gene 
sequence the samples were run on a 1.5% agarose gel to verify the length of the 
amplicon. The gel was run for 20 minutes at 100 V. To stain the DNA 1.5 µl of 
SYBERsafe (Catalog # S33102) was added to the gel prior to pouring heated agarose into 
the casting tray. Gels were imaged with the UV Transillumnator and KODAK (Appendix 
A1 and T1 A1).  
Genotyping. To determine the genotype of the sample numbers for all assays in 
this study, DNA was extracted and isolated (Lot#SLBL553V)). Amplification using 
REdMix. Products from PCR amplification were ran on a 1.5 agarose gel with 1.5µl of 
SYBERsafe. Gels were imaged using the UV transillunator with KODAK image 
software. Example in Figure A2.  
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Results  
Type I Collagen. Type I collagen was a protein of interest for investigating bone 
remodeling because it is the major organic component of the extracellular matrix within 
bone. The normalized expression value for the alpha I chain of Type I collagen for wild-
type was 78.3 copies. In heterozygous mice 80.55 copies were seen, and in IDUA (-/-) 
mice 53.90 copies. Heterozygous mice were found to have 1.02 relative normalized 
expression to wild-type and IDUA (-/-) mice were found to have 0.6883 relative 
normalized expression to wild-type (Table 4). Normalized expression values for the alpha 
II chain of Type I collagen for wild-type was 23.05 copies. In heterozygous mice 29.63 
copies were seen and in IDUA (-/-) mice 3.59 copies (Table 4). Heterozygous mice were 
found to have 1.29 relative normalized expression to wild-type and IDUA (-/-) mice were 
found to have 163 relative normalized expression to wild-type (Table 4). There was no 
significant difference found between genotypes for alpha I chain or alpha II chain of type 
I collagen. (Figure 10).  
Colony Stimulating Factor I. Normalized expression values for the CSF-1 for 
wild-type was 0.1039 copies. In heterozygous mice 0.3697 copies were seen and in 
IDUA (-/-) mice 0.4693 copies (Table 4). Heterozygous mice were found to have -2.705 
relative normalized expression to wild-type (p=0.0942) and IDUA (-/-) mice were found to 
have -2.131 relative normalized expression to wild-type (p=0.00680) (Table 4). A 
decrease expression levels was seen for CSF-1 for IDUA(-/-) mice and heterozygous mice 
compared to wild-type (Figure 11).  
 RANK. Normalized expression for RANK for Wild-type mice was found to be 
0.1831 copies and for heterozygous mice was 0.0493 copies. Animals deficient in  
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Figure 10. Type I Collagen Expression levels as defined by relative 
quantification PCR. Total RNA was isolated from tibiae of wild-type (n=4), 
heterozygous (n=4), and IDUA(-/-) (n=4) mice, transcribed into cDNA and measured for 
relative expression levels of targets by KAPA PROBE qPCR. Targets included Type I 
collagen Alpha chain 1 (COlA1) and Type I collagen alpha Chain 2 (COL1A2). 
Significance was determine if p < 0.05 based on one-way student t- test (CFX Manager 
Verizon 3.0).  
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Figure 11. Expression levels for Biomarkers Involved in Osteoclastogenesis 
as defined by relative quantification PCR. Total RNA was isolated from tibiae of wild-
type (n=4), heterozygous (n=4), and IDUA(-/-) (n=4) mice, transcribed into cDNA and 
measured for relative expression levels of targets by KAPA PROBE qPCR. Targets 
include, Colony Stimulating Factor-1 (CSF-1), osteoprotegerin (OPG), Receptor 
Activator of Nuclear Factor κ B (RANK) and Tumor Necrosis Factor α (TNFα). 
Significance was determine if p < 0.05 based on one-way student t- test (CFX Manager 
Verizon 3.0). Asterisks denotes significance difference between heterozygous to wild-
type (OPG) or significance difference between heterozygous and IDUA (-/-) as compared 
to wild-type (CSF-1), (RANK) and (TNFα).   
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Table 4 Comparison qPCR data. Cycle Threshold values for the genes of interest were 
normalized to Ct values of the housekeeping genes GAPDH and PGK and made relative 
to wild-type. A two-way student t-test was used to calculate the significance value. (For 
p< 0.05 to be significant regulation threshold has to be greater than 4 (R>4). All testing 
group (n=4). 
 
 
 
 
 
Target Genotype 
Me
an 
Cq 
Normalized 
Expression 
Relative 
Normalized 
Expression 
Expression 
SEM 
Regulation 
P 
value  
COL1A1 
Wt 
18.1
4 
78.30 1 0.6199 1 1 
HET 15.7 80.55 1.0287 0.3547 1.029 0.00008 
IDUA(-/-) 16.7 53.90 0.6883 0.3406 -1.453 
0.5237 
COL1A2 
Wt 
19.9
1 
23.05 1 0.6981 1 1 
HET 
17.1
4 
29.63 1.2850 0.4613 1.285 0.0050 
IDUA(-/-) 
17.2
2 
37.59 1.6304 0.7717 1.630 
0.8068 
RANK 
Wt 
26.8
8 
0.1831 1 0.6081 1 1 
HET 
26.3
7 
0.0493 0.2695 0.1045 -3.711 0.0081 
IDUA(-/-) 
26.3
5 
0.0668 0.3640 0.1486 -2.740 0.0060 
OPG 
Wt 
29.8
5 
0.0234 1 0.7964 1 1 
 
HET 
28.3
2 
0.0128 0.5443 0.1731 -1.837 0.2486 
 
IDUA(-/-) 
30.0
6 
0.0051 0.2181 0.1275 -4.585 0.0574 
CSF-1 
Wt 
27.7
0 
0.1039 1 0.5064 1 1 
HET 
26.7
3 
0.0384 0.3697 0.1021 -2.705 0.0942 
IDUA(-/-) 
26.8
1 
0.0487 0.4693 0.1593 -2.131 0.0068 
TNFα 
Wt 
27.9
6 
0.0869 1 0.5122 1 1 
HET 
27.9
7 
0.0163 0.1876 0.0443 -5.332 0.4673 
 IDUA(-/-) 
28.2
0 
0.0186 0.2137 0.0737 -4.679 0.0003 
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IDUA (-/-) were found to have a normalized expression value of 0.0668 copies. Wildtype 
expression of RANK was set to 100% of total expression. Expression of heterozygous 
and IDUA (-/-) were set relative to wildtype expression. Relative normalized expression 
was found to be 2.705 for heterozygous and 2.131 for IDUA (-/-) (Table 4). A decrease 
expression levels was seen for RANK for IDUA(-/-) mice and heterozygous mice 
compared to wild-type (Figure 11).  
Osteoprotegerin (OPG). Expression values for OPG were normalized to the 
housekeeping genes, wild-type mice were found to have 0.0234 copies. Heterozygous 
mice were found to have 0.0128 copies and IDUA (-/-) mice were found to have 0.0051 
copies. Normalized expression values for heterozygous and IDUA (-/-) mice were made 
relative to wild-type normalized expression values. Heterozygous animals were found to 
have 0.5443 and IDUA(-/-) animals were found to have 0.2181 relative expression. (Table 
4).  No change in regulation was seen for heterozygous mice R= -1.837 (p= 0.2486) but 
decrease regulation was observed in IDUA(-/-) mice R= -4.585 (p= 0.0574) (Table 4). A 
decrease expression levels was seen for OPG for IDUA(-/-) mice compared to wild-type 
(Figure 11).  
 Tumor Necrosis Factor α (TNFα). Expression values for TNFα were also 
normalized to the housekeeping genes, wild-type mice were found to have 0.0869 copies. 
Heterozygous mice were found to have 0.0163 copies and IDUA (-/-) mice were found to 
have 0.0186 copies. Normalized expression values for heterozygous and IDUA (-/-) mice 
were made relative to wild-type normalized expression values. Heterozygous animals 
were found to have 0.1876 expression relative to normalized wild-type expression. 
Lastly, IDUA(-/-) animals were found to have 0.2181 to normalized. Decreased regulation  
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was seen in both heterozygous -5.332 (p= 0.4673) and IDUA(-/-) -4.679 (p= 0.0003) 
(Table 6). Decrease expression was also seen for TNFα (Figure 11). 
Results Summary. No difference was noted between the genotypes for the 
mRNA levels of COLA1 and COLA2. The mRNA levels for RANK, TNFα, and CSF-1 
all showed a decreasing trend for IDUA(-/-) mice and heterozygous mice compared to 
wild-type, suggesting a decrease in stimulus leading to osteoclastogenesis. Lastly, mRNA 
levels of OPG were observed to be decreased in IDUA(-/-) deficient mice compared to 
wild-type mice.  
 
Discussion and Conclusion 
Type I Collagen. The main component of the organic matrix of bone is type I 
collagen, a triple helical protein formed from two α (I) chains and one α (II) chain. 
Transcript levels of both chains were not observed to be different in heterozygous and 
IDUA(-/-) mice compared to wild-type as determined by mRNA levels found by qPCR 
analysis. Various sources have seen an increase in bone mineral density in lysosomal 
storage disease models compared to nondisease models. As later sources point out the 
BMD data were not analyzed with body weight as a covariate providing false conclusions 
about the change in BMD. As mentioned previously, Raman Spectroscopy showed no 
changes in the Bone Mineral Density Distribution (BMDD) when relating the graylevel 
(atom number) to calcium content (Figure 5). Calcium is a part of the inorganic material 
(hydroxyapatite) of bone which attaches at specific areas along Type I collagen. From the 
collective evidence of Raman Spectroscopy, PINP concentrations determined by ELISA 
(Table 3) and quantification of Type I collagen mRNA levels (Figure 10) altered 
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distribution of hydroxyapatite and type I collagen is not a downstream effect of GAG 
accumulation.  
Genes Affecting Osteoclastogenesis (CSF-1, RANK & OPG). Bone remodeling 
begins with activation of the osteoclasts, including the stimulation of hematopoietic stem 
cells into osteoclast-precursors and fusion of osteoclast-precursors into multinucleated 
mature osteoclasts. Survival and proliferation of osteoclast-precursors is dependent on the 
cytokine CSF-1. This cytokine is also required for the survival of mature osteoclasts and 
for the cytoskeleton rearrangement needed for polarization of mature osteoclasts. 
Decreased relative normalized expression was observed to be significant but need not 
reach above regulated regulation threshold,  for both heterozygous (0.3697) and IDUA(-/-) 
(0.4693) mice compared to wild-type mice (1) (Table 6 and Figure 10). A decrease in 
CSF-1 would affect the ability of osteoclast-precursors to survive and proliferated into 
mature osteoclasts, decreasing the tissue’s ability to produce actively resorbing 
osteoclasts.  
Osteoblasts and fibroblasts secrete the ligand for RANK (RANKL) into the 
extracellular matrix where it will bind to RANK located on the surface of osteoclasts. 
The formation of the RANKL/RANK complex activates a signaling cascade to turn on 
transcription of genes promoting the fusion of osteoclast-precursors into multinucleated 
mature osteoclasts. Decreased relative normalized expression was found for both 
heterozygous (0.2695) and IDUA(-/-) (0.3640) mice compared to wild-type mice (1).  A 
decrease in RANK would affect the ability of osteoclast-precursors to fuse into mature 
osteoclasts, lowering the number actively resorbing osteoclasts. The lower number of 
osteoclasts could contribute to the increase in cortical bone width and increased marrow 
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diameter. Theses changes may contribute to the change in femur geometry suggested 
compensate for the alterations in the properties of strength. 
However, as noted earlier there was not a change in serum levels of TRAP5b 
between the genotypes indicating no change in the number of osteoclasts. However the 
use of ELISA to measure TRAP5b may not have the sensitivity required to detect 
changes between MPS I model and an unaffected model. Which may be accounted for by 
the observed decrease in relative expression of OPG for IDUA(-/-) (Figure 10), the decoy 
receptor of RANKL. OPG is used as a control mechanism for stimulation of 
osteoclastogenesis by blocking the binding of RANKL to RANK. The observed 
decreased would counteract the decrease seen RANK and possibly CSF-1.  
Tumor Necrosis Factor α (TNFα).  Finally, mRNA levels of TNFα were seen to 
be decreased in heterozygous and IDUA(-/-) compared to wild-type. TNFα is believed to 
reduce bone formation by mature osteoblasts and increase bone resorption by osteoclasts. 
A decrease in TNFα could suggest increase in bone formation due to inactivation of the 
bone formation cellular pathways limiting mineralization. Further this could result in a 
decrease in bone resorption. Notably, the signaling pathways for TNFα are complex and a 
decrease in mRNA expression could have other effects other than the ones mentioned.  
 
Conclusions and Future Directions 
Mucopolysaccharidosis Type I (Hurler Syndrome) devastating lysosomal storage 
disease resulting in death in early adulthood due to the progressive accumulation of HS 
and DS. This accumulation is due to a deficiency of producing α-L-iduronidase. 
Inevitable degeneration of multiple organ systems occurs by mechanisms yet to be fully 
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understood. Current treatments have been able to decrease the accumulation of GAGs 
and improve quality of life however progression of dysostosis multiplex continues to 
worsen. Patients with MPS1 require painful surgery intervention to treat the bone 
abnormalities despite treatment with enzyme replacement therapy and hematopoietic 
stem cell transplantation. 
The purpose of this study was to investigate bone metabolism between wild-type, 
heterozygous and IDUA(-/-) mice by analyzing bone remodeling biomarkers. Bone 
resorption was investigate by analyzing concentrations of PINP and the mRNA 
concentrations of type I collagen. No significant difference was observed between 
IDUA(-/-) mice and wildtype for PINP concentrations and mRNA concentrations of alpha 
I chain and alpha 2 chain of Type I collagen suggesting a deficiency in IDUA does not 
alter the level of bone formation. 
The level of bone resorption was also investigated within this study by analyzing 
the concentrations of TRAP5b and mRNA concentrations of osteoclastogenesis 
biomarkers. Those osteoclastogenesis included, Colony Stimulating Factor-1 (CSF-1), 
osteoprotegerin (OPG), Receptor Activator of Nuclear Factor κ B (RANK) and Tumor 
Necrosis Factor α (TNFα). No significant difference was found for the concentrations of 
TRAP5b between the genotypes. However, there was a difference observed between the 
genotypes for the biomarkers of osteoclastogenesis. The down regulation observed in the 
mRNA levels in CSF-1, RANK and TNFα indicates decrease osteoclastogenesis since 
their protein forms stimulate the differentiation of hematopoietic stem cell into 
osteoclasts. However the down regulation of OPG indicates an increase in 
osteoclastogenesis since OPG is a decoy receptor for RANK, providing a negative 
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feedback for osteoclastogenesis. Overall a definitive change in bone resorption due to 
accumulation of GAG cannot be determined from this study.  
To further investigate changes in bone metabolism intracellular signaling 
pathways should be evaluated. Disruptions in downstream in RANK pathways could be 
altered by the accumulation of GAG within hematopoietic stem cells and pre-osteoclasts. 
Secondly, since osteoclasts were seen to have an inability to attach to the bone matrix in a 
similar lysosomal storage disease (Monroy et al 2002) the molecular interactions 
involved in the formation the podosomes should be investigated. The binding of β-
integrin in osteoclasts to RDG rich proteins located in the bone matrix could be disrupted 
by the accumulation of GAG. Also the formation of the ruffled border on osteoclasts may 
be disrupted by the accumulation of GAGs.  
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APPENDICES 
 
Appendix A. 
Length of amplicon in base pairs (Applied Biosystems) Targets included Type I collagen 
Alpha chain 1 (COlA1), Type I collagen alpha Chain 2 (COL1A2), Colony Stimulating 
Factor-1 (CSF-1), osteoprotegerin (OPG), Receptor Activator of Nuclear Factor κ B 
(RANK) and Tumor Necrosis Factor α (TNFα) 
 
 
 
Appendix B Amplicon Length Verification 
Products from qPCR were ran on a 1.5% gel with 1.5 µl of Sybersafe to ensure 
amplification of the correct target A) Targets GAPDH, PGK1, OPG, COLA1, B) TNFα, 
CSF-1, RANK, and COLA2.  
 
 
 
GENE Amplicon Length (bp) 
COLA1 89 
COLA2 77 
CSF-1 70 
RANK 65 
OPG 75 
TNFα 81 
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Appendix C. Verification of GAPDH and PGK1 as Normalizing Genes for qPCR 
 
 
 
 
 
 
 
 
Appendix D. 
Genotyping gel Example Samples in order: 405-409, 413-415. Sample 409 was loaded 
into lanes 9 and 10. A nonmutated allele is 613bp and a IDUA-W392X  knockout allele is 
576bp. Heterozygous animals will have two distinct bands, wild-type animals had one 
band at 576bp and IDUA(-/-) animals had one band at 613bp. A 100bp DNA ladder 
(Promega) was loaded into lane 6 and Lane 11 contains the negative control.  
 
Gene GAPDH PGK1 
Average Ct in Wt 19.33 21.67 
Average Ct in IDUA(-/-) 18.64 22.3 
N 2 2 
      1       2       3       4       5      6      7       8       9      10    11 
